Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon-induced apoptosis

Journal of Dermatology

Volumn 40, Issue 8, 2013, Pages 596-605

  Gu, Xiaoguang ^a   Wang, Yang ^a   Zhang, Gaolei ^a   Li, Weiwei ^a   Tu, Ping ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

BCL11B; Hut78; interferon 2b; methotrexate; mycosis fungoides

Indexed keywords

ALPHA2B INTERFERON; BCL11B PROTEIN; KRUPPEL LIKE FACTOR; MESSENGER RNA; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; UPREGULATION;

BCL11B; HUT78; INTERFERON-Α-2B; METHOTREXATE; MYCOSIS FUNGOIDES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOPSY; CASE-CONTROL STUDIES; CELL LINE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; MALE; METHOTREXATE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; YOUNG ADULT;

EID: 84881475560     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12160     Document Type: Article

References (43)

1. Hwang ST, Janik JE, Jaffe ES, Wilson WH,. Mycosis fungoides and Sezary syndrome. Lancet 2008; 371 (9616): 945-957.
2. Willemze R, Jaffe ES, Burg G, et al,. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105 (10): 3768-3785.
3. Olsen E, Vonderheid E, Pimpinelli N, et al,. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110 (6): 1713-1722.
4. Arai E, Katayama I, Ishihara K,. Mycosis fungoides and Sezary syndrome in Japan. Clinicopathologic study of 107 autopsy cases. Pathol Res Pract 1991; 187 (4): 451-457.
5. Campbell JJ, Clark RA, Watanabe R, Kupper TS,. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116 (5): 767-771.
6. van Doorn R, van Kester MS, Dijkman R, et al,. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113 (1): 127-136.
7. Wang Y, Su M, Zhou LL, et al,. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood 2011; 117 (14): 3826-3835.
8. Avram D, Fields A, Pretty On Top K, Nevrivy DJ, Ishmael JE, Leid M,. Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors. J Biol Chem 2000; 275 (14): 10315-10322.
9. Liu P, Li P, Burke S,. Critical roles of Bcl11b in T-cell development and maintenance of T-cell identity. Immunol Rev 2010; 238 (1): 138-149.
10. Albu DI, Feng D, Bhattacharya D, et al,. BCL11B is required for positive selection and survival of double-positive thymocytes. J Exp Med 2007; 204 (12): 3003-3015.
11. Wakabayashi Y, Watanabe H, Inoue J, et al,. Bcl11b is required for differentiation and survival of alphabeta T lymphocytes. Nat Immunol 2003; 4 (6): 533-539.
12. Li P, Burke S, Wang J, et al,. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science 2010; 329 (5987): 85-89.
13. Salgado R, Servitje O, Gallardo F, et al,. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol 2010; 130 (4): 1126-1135.
14. Sakata J, Inoue J, Ohi H, et al,. Involvement of V (D) J recombinase in the generation of intragenic deletions in the Rit1/Bcl11b tumor suppressor gene in gamma-ray-induced thymic lymphomas and in normal thymus of the mouse. Carcinogenesis 2004; 25 (6): 1069-1075.
15. Wakabayashi Y, Inoue J, Takahashi Y, et al,. Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas. Biochem Biophys Res Commun 2003; 301 (2): 598-603.
16. Gutierrez A, Kentsis A, Sanda T, et al,. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood 2011; 118 (15): 4169-4173.
17. De Keersmaecker K, Real PJ, Gatta GD, et al,. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med 2010; 16 (11): 1321-1327.
18. Kamimura K, Ohi H, Kubota T, et al,. Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development. Biochem Biophys Res Commun 2007; 355 (2): 538-542.
19. Huang X, Chen S, Shen Q, et al,. Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 2010; 3 (1): 44.
20. Oshiro A, Tagawa H, Ohshima K, et al,. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006; 107 (11): 4500-4507.
21. Fujimoto R, Ozawa T, Itoyama T, Sadamori N, Kurosawa N, Isobe M,. HELIOS-BCL11B fusion gene involvement in a t (2;14) (q34;q32) in an adult T-cell leukemia patient. Cancer Genet 2012; 8: 356-364.
22. MacLeod RA, Nagel S, Kaufmann M, Janssen JW, Drexler HG,. Activation of HOX11L2 by juxtaposition with 3′-BCL11B in an acute lymphoblastic leukemia cell line (HPB-ALL) with t (5;14) (q35;q32.2). Genes Chromosom Cancer 2003; 37 (1): 84-91.
23. Grabarczyk P, Nahse V, Delin M, et al,. Increased expression of bcl11b leads to chemoresistance accompanied by G1 accumulation. PLoS ONE 2010; 5 (9): e12532.
24. Su MW, Dorocicz I, Dragowska WH, et al,. Aberrant expression of T-plastin in Sezary cells. Cancer Res 2003; 63 (21): 7122-7127.
25. Tracey L, Villuendas R, Ortiz P, et al,. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol 2002; 161 (5): 1825-1837.
26. Wu J, Wood GS,. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011; 147 (4): 443-449.
27. Girardi M, Heald PW, Wilson LD,. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350 (19): 1978-1988.
28. Golonzhka O, Liang X, Messaddeq N, et al,. Dual role of COUP-TF-interacting protein 2 in epidermal homeostasis and permeability barrier formation. J Invest Dermatol 2009; 129 (6): 1459-1470.
29. Yanase N, Kanetaka Y, Mizuguchi J,. Interferon-alpha-induced apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent and -independent manner. Oncol Rep 2007; 18 (4): 1031-1038.
30. Yanase N, Hata K, Shimo K, Hayashida M, Evers BM, Mizuguchi J,. Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res 2005; 310 (1): 10-21.
31. Du LQ, Du XQ, Bai JQ, et al,. Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells. J Cancer Res Clin Oncol 2012; 138 (5): 811-818.
32. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS,. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129 (5): 1165-1173.
33. Frei GM, Kremer M, Hanschmann KM, et al,. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101. Br J Dermatol 2008; 158 (3): 578-586.
34. Klemke CD, Brenner D, Weiss EM, et al,. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death. Cancer Res 2009; 69 (10): 4175-4183.
35. Cismasiu VB, Adamo K, Gecewicz J, Duque J, Lin Q, Avram D,. BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter. Oncogene 2005; 24 (45): 6753-6764.
36. Cismasiu VB, Duque J, Paskaleva E, et al,. BCL11B enhances TCR/CD28-triggered NF-kappaB activation through up-regulation of Cot kinase gene expression in T-lymphocytes. Biochem J 2009; 417 (2): 457-466.
37. + T lymphocytes. Blood 2006; 108 (8): 2695-2702.
38. + T lymphocytes depend on the transcription factor Bcl11b. J Exp Med 2010; 207 (8): 1687-1699.
39. Chen S, Huang X, Yang L, et al,. The role of BCL11B in regulating the proliferation of human naive T cells. Hum Immunol 2012; 73 (5): 456-464.
40. Grabarczyk P, Przybylski GK, Depke M, et al,. Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene 2007; 26 (26): 3797-3810.
41. Olsen EA,. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16 (4): 311-321.
42. Schindler C, Levy DE, Decker T,. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282 (28): 20059-20063.
43. Shibata T, Shimada Y, Shimoyama M,. Time-dependent cytotoxic action of human recombinant alpha-interferon (Ro22-8181) in vitro and the sensitivity of various cultured leukemia and lymphoma cell lines to it. Jpn J Clin Oncol 1985; 15 (1): 67-75.